In a review of recently published scientific studies, researchers at Columbia Engineering and the University of Wisconsin-Madison identified a library of molecules that can shut down the polymerase reaction in the SARS-CoV-2 virus that causes COVID-19.
If you are not happy with the results below please do another search
50 search results for:
Recent personnel movement within the healthcare industry includes a new CEO for Scenic Biotech.
The European Commission gave conditional approval for the use of remdesivir in severe COVID-19 patients following an accelerated review process, making the antiviral the region’s first authorized therapy to treat the virus.
COVID-19 vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said.
Only a few weeks after announcing receipt of a green light from the U.S. Food and Drug Administration to begin a 30,000-patient Phase III clinical trial of a COVID-19 vaccine, Moderna indicated the start date was pushed back.
The United States reported more than 55,000 new COVID-19 casesy, a new daily global record for the coronavirus pandemic, as infections rose in a majority of states.
The U.S. Food and Drug Administration approved GlaxoSmithKline Plc’s HIV drug Rukobia to treat adult patients who have run out of treatment options.
Regeneron Pharmaceuticals and Sanofi said their rheumatoid arthritis drug Kevzara failed to meet the main goals of a U.S. study testing the medicine in the most critically ill COVID-19 patients.
The U.S. Food and Drug Administration approved ViiV Healthcare’s Rukobia (fostemsavir) as a first-in-class treatment for HIV in adults with few treatment options available.
South San Francisco-based Annexon, focused on drugs for autoimmune and neurodegenerative disorders, closed on a $100 million Series C financing led by Redmile Group.